JP Patent

JP7402685B2 — （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用

Assigned to ベイジーン スウィッツァーランド ゲーエムベーハー · Expires 2023-12-21 · 2y expired

What this patent protects

Patent listed against Brukinsa.

Drugs covered by this patent

Patent Metadata

Patent number
JP7402685B2
Jurisdiction
JP
Classification
—
Expires
2023-12-21
Drug substance claim
No
Drug product claim
No
Assignee
ベイジーン スウィッツァーランド ゲーエムベーハー
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.